Prostate Cancer - Results from #1400

Impact of Prostate Size on the Functional and Oncological Outcomes of Robot-assisted Radical Prostatectomy. February 1, 2024

The Ability of the STAR-CAP Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 Prostate Cancer. February 1, 2024

Robustness of magnetic resonance imaging and positron emission tomography radiomic features in prostate cancer: Impact on recurrence prediction after radiation therapy. February 1, 2024

Learning curve for fusion magnetic resonance imaging targeted prostate biopsy and three-dimensional transrectal ultrasonography segmentation. February 1, 2024

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium January 31, 2024

Current practice and unmet training needs in robotic-assisted radical prostatectomy: investigation from the Junior ERUS/YAU working group. January 31, 2024

Nonsurgical Interventions to Prevent Disease Progression in Prostate Cancer Patients on Active Surveillance: A Systematic Review and Meta-analysis. January 31, 2024

Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL). January 31, 2024

Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer. January 31, 2024

Updates on Management of Biochemical Recurrent Prostate Cancer. January 31, 2024

Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations. January 30, 2024

PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence. January 30, 2024

Single port robot-assisted radical and simple prostatectomy: a systematic review and meta-analysis. January 30, 2024

Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images. January 30, 2024

Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study. January 30, 2024

Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort. January 29, 2024

Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway. January 29, 2024

The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic Resonance Imaging-targeted Prostate Biopsy. January 29, 2024

15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis. January 29, 2024

A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). January 29, 2024

Page 71 of 1435